The authors are affiliated with the UMR Xénobiotiques,
Introduction
Dietary changes might prevent 70-80% of colorectal cancer, a major cause of death in nonsmokers (1) . Diet may carry chemopreventive agents that could reduce the cancer risk. These agents can inhibit the initiation of preneoplastic lesions by carcinogens, or reverse their progression to invasive cancers. More than 300 agents have been tested in rodents: most of them were fed to rats, during or after the injection of a colon carcinogen. The aim of those animal studies is to detect potent and non-toxic chemopreventive agents that might eventually be given to people, to reduce their risk of colorectal cancer.
Few agents have indeed been tested in randomized doubleblinded human trials. Most tested agents showed no preventive effect: the risk of polyp recurrence was not reduced in volunteers fed for years with supplements of wheat bran, vitamin E and C, beta-carotene, or psyllium (2-7), or induced to eat less fat or more fruits and vegetables (6) (7) (8) . Supplemental calcium decreased by 15-20 % the polyp recurrence in volunteers (9) . Celecoxib, a NSAID, decreased by 30% the number of polyps in FAP patients (10) . In addition, other human intervention studies showed a preventive effect of selenium, sulindac, ursodeoxycholic acid, N-acetylcysteine, or lactulose. But these studies were not definite: colon tumors were not the primary endpoints, the number of patients was small, or the treatment was not double-blinded (11) (12) (13) (14) (15) . Clearly, no agent is yet ready for colon cancer chemoprevention in humans, except, may be, calcium and celecoxib.
Before 1990, the gold standard endpoint for chemoprevention in rodents was the incidence of macroscopic tumors: colon adenomas and adenocarcinomas induced by a chemical carcinogen. These endpoints are clearly related to cancer, but have three major drawbacks: (i) a tumor requires a long time to develop (usually 5-8 months), (ii) each tumor must be confirmed by histology, which is long and costly, and (iii) each animal brings little information to the study (each rat has either no tumor or a tumor), thus large groups of rats are needed for statistical analysis. In 1987, Bird described putative precursors of colon cancer, aberrant crypt foci (ACF), first detected in rodents few weeks after carcinogen injection (16) . The crypts in ACF are easy to score on whole mount colon: they are two to three times larger than normal crypts, are microscopically elevated, have a slit-like opening, a thick epithelial lining that stains darker than normal crypts 2 with a large pericryptal zone (17) . It was demonstrated that: (i) ACF were induced by all colon carcinogens in a dose-and species-dependant manner; (ii) their number and growth were modified by the modulators of colon carcinogenesis, and they predicted the tumor outcome in several rodent studies; (iii) they correlate with colon cancer risk, and adenoma size and number in humans; (iv) the morphological and genotypic features of ACF in human colons were similar to those in animal colons, and many alterations are similar in ACF and in tumors; (v) some ACF show dysplasia, and carcinoma were observed in rodents and humans' ACF (18) (19) . The use of the ACF system to study modulators of carcinogenesis has accelerated for the last 10 years, for it provides a simple and economical tool for preliminary screening of potential chemopreventive agents, and it allows a quantitative assessment of the mechanisms of colon carcinogenesis (20) . However, the preneoplastic nature of ACF is controversial, and other premalignant lesions were recently described in the rat colon (21) .
The major goal of this study was to point out the most potent chemopreventive agents already published. To reach this goal, we had three minor aims: (i) to gather all published studies on the effect of dietary chemopreventive agents against colon carcinogenesis in rats (or mice) after carcinogen injection, (ii) to rank the agents, according to their potency to inhibit colon ACF on the one hand, and colon tumors on the other hand. Ranking is a critical step that can help to set priorities when selecting agents for human trials. These ranked lists could be used to choose an agent provided it is not toxic. This attempt is similar to the ranking of carcinogenic hazards published by Ames and Gold (22) (iii) to test the hypothesis that the potencies of agents in the ACF assay and in the tumor assay are correlated.
Materials and Methods.
All publications on the effect of dietary chemopreventive agents against colon carcinogenesis in rodents, and cited in the Current Contents Life Science from January 1989 to December 2001, were obtained from their authors. In addition, searches were done on the Medline data base, and on the web sites of the American Association for Cancer Research, and of the journals Carcinogenesis and Cancer Letters. Studies of specific agents were collected, as well as dietary studies. Each article was carefully read, and seven of them were rejected due to low plausibility. In addition, some engaging articles do not report suitable quantitative data (e.g., 23-25). We did not include obvious toxic agent, e.g., methylcholanthrene (26). Articles reporting non-significant protection, or a promoting effect, were not included either.
Because our goal was to point out the most potent chemopreventive agents, we kept only the single most potent agent and dose from each article. However, some articles deal with many agents (e.g., 27). From the thirty articles dealing with more than seven agents, we kept more than one agent. From each study, we decided to keep the most potent agent out of seven. In other words, we kept the top 14 percent agents from large studies. We inferred data from the height of the bars, when the original paper gives a histogram instead of a table.
Data were gathered from 137 articles with the ACF endpoint, yielding 186 ACF preventive agents (because two or more agents were kept form articles dealing with more than seven agents). A primary ACF table (not shown) was built containing the mean number of total ACF per colon, of large ACF per colon, and of crypts per ACF in each group of rats (control and treated). In most studies, a "large ACF" contains four or more crypts. Data were also gathered from 146 articles with the tumor endpoint, yielding 160 tumor preventive agents or diets. A primary tumor table (not shown) was built with the incidence of tumors, the incidence of invasive carcinomas, and the mean tumor multiplicity in each group of rats (control and treated). Data from each article were double-checked by the second author, independently from the first one.
A potency index was then estimated for each agent in each study, by calculating the ratio of mean value in control rats divided by mean value in treated rats. For instance, in the Wargovich's study (27) , a mean number of 193 ACF was observed in control rats, and of 28 ACF in rats given sulindac sulfide: the potency of sulindac sulfide to reduce the ACF number was calculated as 193/28 = 6.89. As an other example, in the Corpet's study (28), the incidence of tumors (confirmed by histology) was 22/27 in the control group, and 2/21 in the group of rats given polyethylene glycol (PEG): the potency of PEG to reduce the tumor incidence was calculated as (22/27)/(2/21) = 8.55. Thus, potency tells the times-fold reduction in a carcinogenesis endpoint due to the agent. When incidence is concerned, potency is the inverse of the relative risk (e.g., a potency of 8.55 corresponds to a relative risk of 0.12). This article reports ACF and tumor potency tables (tables 1 and 2). In addition, to help the reader, some endpoints were also reported as percent inhibition afforded by the agent, which is equal to 100 -100/potency (e.g., a potency of 8.55 gives a 88.3% inhibition). When no tumor was seen in the control group, potency calculation was arbitrarily based on 0.5 tumors in the group. Our potency estimate does not take in account the dose used. We chose not to include the dose in the potency calculation, because most treatments were close to the maximum tolerated dose (40 or 80%): the authors often used the highest possible dose they could, to get the maximum protection. For instance, non-toxic agents like dietary fibers can be included in both rodent and human diets at a much higher level than agents that are more toxic and possibly more potent to prevent cancer (e.g., selenium, retinoids, and NSAIDs). The experimental design of each study was recorded, but not fully shown here: the animal species and strain, the initiating carcinogen and doses, the treatment dose and duration. If the agent was given during the time of exposure to the carcinogen, the protocol was labeled "init" for initiation, if it was given after initiation, the label was "post" for post-initiation. In most studies, the agent was given to rats during both periods (during and after the carcinogen): these protocols were labeled "both." The postinitiation protocol has more clinical relevance since it may identify agents that prevent the recurrence and progression of precursor lesions for colon cancer (27). Most studies were done in rats initiated with dimethylhydrazine or its metabolite azoxymethane (237/283) . We also chose to include in this review the few chemoprevention studies done with carcinogens different from dimethylhydrazine or azoxymethane (24/283) , and the studies done in the mouse (22/283) , because some promising agents were tested only in the mouse (e.g., protease inhibitor, sphingomyelin).
Each agent was classified within a class of agents, Table 1 shows the efficacy of chemopreventive agents on ACF endpoints. The agents were ranked according to their potency to reduce the number of ACF per rat. Most potent agents are thus placed on the top of the table, and eleven articles report agents that reduce the ACF number by more than 80% (potency higher than 5). The most potent agents were pluronic (potency 76, i.e., pluronic treatment reduced 76-fold the ACF number), PEG (potencies of 56, 18, 14, 8 and 5.5 in five independent articles), perilla oil associated with beta-carotene (potency 11), indole-carbinol (potency 11 on imidazopyridine-induced ACF, but control rats had only 3 ACF/rat), a NO-releasing aspirin derivative (potency 7 on TNBS-DMH-induced ACF), sulindac sulfide (potency 7), and a caffeic acid ester (potency 5.6). Among the 186 agents in the ACF table, the median agent halved the number of ACF (median potency, 2). Indole-carbinol, PEG (three studies), chlorophillin, cork, pluronic, sanshishi, auraptene (two studies), troglitazone, zerumbone, ursodeoxycholic acid and hesperidin were the most potent agents to reduce the ACF size (or crypt multiplicity), a marker of the ACF growth rate. As shown in table 1, each agent was attributed to a class (last column). The mean potencies of all agents in each class on ACF were calculated, compared by ANOVA analysis, and shown on figure 1 as percent inhibitions (hatched bars). PEG class was significantly more potent than any other class (ANOVA p<0.0001). No significant difference was seen among the eight other classes (PEG-omitted ANOVA p=0.28). Table 2 shows the efficacy of chemopreventive agents on tumor endpoints. The agents were ranked according to their potency to reduce the incidence of tumors in the colon and rectum. Sixteen articles report agents that reduce the tumor incidence by more than 80% (potency higher than 5). The most potent agents were celecoxib (potency 15), piroxicam or aspirin with DFMO (potencies 9 or 5.3), PEG (potencies of 8.6 and 7 in two independent articles), S-methyl methane thiosulfonate (MMTS, potency 7.9), Bifidobacterium longum (potency higher than 7 against imidazoquinoline initiation), a protease inhibitor (potency 10.4 and estimated 7.3 in two mice's studies), folic acid (potency 7), piroxicam (potency 6.5), pectin (potency 5.7), obacunone (potency 5.5), and magnesium hydroxide (potency 5.3). Most of these agents were included in the diet during both initiation and promotion phases, and only PEG, MMTS, piroxicam, and obacunone were effective after the end of the initiation period (protocol labeled "post" in table 2). Some potencies were not accurately established, because the tumor incidence was small in the control group. It was often the case for the most potent agents. Indeed, potency of B. longum, protease inhibitor, folic acid, and calcium glucarate, were based on only 7 tumorbearing rats or mice in their respective control group (see  table 2 , column 5).
Results

Figure 1.
Mean potency of all chemopreventive agents in each class to reduce number of aberrant crypt foci (ACF) and tumor incidence in colon of rats. Nine classes are as follows: polyethylene glycol (PEG), difluoromethylornithine and amine modulators (/NH2), nonsteroidal antiinflamma-tory drugs (NSAID), calcium and other mineral salts, lipids (mostly n-3 polyunsaturated fatty acids), phytochemicals and plant extracts (phytochem), fibers and bacteria, vitamins A and D and retinoids, and others. Bars, mean percent inhibition of treated group compared with control group; error bars, SEM.
Among the 160 agents in table 2, the median agent halved the tumor incidence (median potency, 2). No carcinoma was detected (100% inhibition of cancer) in rats fed ursodeoxycholic, PEG (two independent studies) or MMTS, and in rats given exercise. In addition, celecoxib, acetoxychavicol, selenium, p53 vaccination, piroxicam with DFMO, cellulose, aspirin, S-allylcysteine, obacunone, sulindac sulfone and hesperidin (two studies) reduced the incidence of adenocarcinoma more than 78%. Each agent was attributed to one of nine classes, as in table 1. The mean potency of agents in each class were calculated, compared by ANOVA analysis, and shown on fig. 1 as percent inhibition of the tumor incidence (solid bars). The mean potency of NSAIDs, PEGs, and amine modulators were not different, but PEG class was significantly more potent than the six other classes (ANOVA p=0.0004). When PEG was omitted, the ANOVA remained significant (p=0.02), but NSAIDs and amine modulators were not significantly more potent than any of the other classes (all pairwise p were larger than 0.05).
In an attempt to combine results from both tables, we merged the six tabulated endpoints in a non-parametric way. Tables 1 and 2 were ranked sequentially according to potency of each agent to reduce (i) the number of ACF, (ii) the number of large ACF, (iii) the number of crypts per ACF, (iv) the tumor incidence, (v) the adenocarcinoma incidence, and 
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(vi) the tumor multiplicity. Obviously, these endpoints are partly redundant, but they do not fully overlap. We gathered the top-twenty agents against each endpoint in a list of 120 items (not shown). Agents cited most often in this list were then PEG 8000 (cited 20 times), DFMO alone or with piroxicam or aspirin (8 times), a protease inhibitor (5 times), celecoxib, hesperidin, sulindac sulfone or sulfide, and Bifidobacterium (4 times each). Other agents appeared 3 times or less in the table: they may be potent agents too, but have been reported in few articles yet. Making the list with top-12 agents instead of top-20 did not change much the most-cited agent list. Tables  1 and 2 are shown on logarithmic scales. Points between 1.5 and 3 were too tight to be labeled. GOS, glucooligosaccharide; TGF-Β1, transforming growth factor-Β1; BHA, butylated hydroxyanisole; DFMO, difluoromethylornithine; DHA, docosahexaenoic acid.
Fifty-seven agents were found in both table 1 and 2. A significant correlation was found between the potencies in the ACF assay and in the tumor assay (r=0.45, N=57, p<0.001). As shown on fig. 2 , celecoxib is very potent against tumors, but not against ACF. It thus appeared as a major outlier in the tumor-ACF correlation. When this outlying point was dropped, correlation increased to r=0.68 (N=56, p<0.001). The faster ACF grow, the larger they become. Thus the ACF size may relate more closely to the tumor endpoint than the ACF number (160, 293, 294). However, many articles do not report ACF size or large ACF number, and correlation could be calculated from fewer points than above. Correlation of the tumor incidence with ACF multiplicity was r=0.69 (p=0.005, N=20), and with the number of large ACF was r=0.76 (p<0.001, N=36).
Discussion
This review of the literature proposes a ranking of the most potent agents detected in rodents' studies, and supports the notion that ACF may be used as a surrogate endpoint for tumors in rats. We will discuss possible bias in the ranking (publication bias and selection process bias) before showing possible extensions of the work. We will then discuss correlation between ACF and tumor, also looking for bias, trying to explain the outlying point, and concluding that ACF may be used as surrogate endpoints. We will not discuss here the mechanisms of inhibition, already addressed in reviews (e.g., 295, 296) .
By combining six carcinogenesis endpoints from tables 1 and 2, this review suggests that the most potent agents are PEG 8000, a protease inhibitor, DFMO alone or with piroxicam or aspirin, hesperidin, celecoxib, sulindac sulfone or sulfide, and Bifidobacteria strains. One may prefer to rely on a single endpoint (e.g., cancers), which would result in a slightly different list (Table 2 ). Our non-parametric ranking takes in account both the potency of the agent, and the number of studies published on it. This may be seen as a publication bias, but it is also a measure of the strength of the evidence. We think the most potent agents cited above are promising for cancer prevention, and should be tested in people at risk. However, agents with low potency can also be valuable, particularly those that are naturally present in foods. We like better the idea to prevent cancer by eating intact plant food with the multiplicity of agents that they contain, than by packaging potent anticarcinogenic constituent in a daily pill. However, up to now, we have no direct evidence that the first approach is efficient.
It is likely that this review missed some articles, particularly those published before 1989 and very recent ones. However, we think that no potent agents could be missed: the early comprehensive review of Angres and Beth (297) points out the protective effect of wheat bran, cellulose, low fat, selenium and caloric restriction. Each of these factors is cited several times in table 2, but we did not report all early studies. For instance, although we reported many studies on the chemoprevention by fish oil or by n-3 fatty acids, only five studies on low-fat diet were included. One reason is that a low-fat diet is not exactly a "chemopreventive agent." Another reason is that the protection afforded by low-fat diets is often small. Indeed, a meticulous review of 14 studies of dietary fat and rat colon carcinoma shows that fat has no effect in one study out of two (298). Specifically, no association between colon cancer incidence and fat intake is seen for Sprague-Dawley rats, but a positive relationship is indicated for Fischer 344 rats. When the degree of saturation is taken into account, only n-6 polyunsaturated fat intake significantly promotes the cancers. We used the logistic regression analysis from the quantitative review (298), to calculate the "potency" of a low-fat diet to reduce the cancer incidence in Fisher 344 rats. Compared with a high-fat diet (20% fat), the median potency of a low-fat diet (5% fat) to reduce the cancer incidence was 1.3, which is in the bottomten of table 2.
Because our first aim was to find the most potent agents against colon carcinogenesis, we used a selection process to build the tables. The result could thus mislead the reader for some agents: (i) Some potent agents are not shown in the tables because they were hidden by a more potent one in the same article. This is the case, for instance, of limonin. This citrus limonoid was reported in the same article as obacunone (54). Both were very potent to prevent ACF and tumors, but we dropped limonin since obacunone was more potent.
(ii) Some agents rank very high in the tables, but are less potent in duplicated studies. For instance, MMTS reduces 8-fold the tumor incidence in a first study (170), but has little effect (1.1-fold reduction) in a duplicated study (285) .
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(iii) Some agents might have been dropped from the tables, if negative studies had been taken in account too, and if mean potencies have been calculated for each agent. For instance, a specific nitric oxide synthase inhibitor prevents colon carcinogenesis (147), but can also promote carcinogenesis (299). Similarly, many agents shown here as preventive, did enhance carcinogenesis in other rat studies (e.g., betasitosterol, benzyl-and phenylhexyl-isothiocyanates, calcium, cellulose, diallyl sulfide, folic acid, genistein, germfree status, glucarate, pectin, quercetin, resistant starch, rutin, selenium, tea extracts, vegetables and fruits mixture, and vitamin D3). Thus, the tables may help to find the most potent agents, but cannot be used to calculate the average effect of a given agent.
The present work could be extended in four directions: (i) The tables could be updated when new agents are published. We propose to do this on a website with sorting abilities (http://www.inra.fr/reseau-nacre/corpet).
(ii) It could be useful to have a comprehensive view of all the studies on colon cancer chemoprevention in rodents. Thus, all results from each paper should be included in the tables, including less potent agents and those that promote carcinogenesis. This would allow the calculation of the mean potency of each agent. However, since most negative results are not published, a large publication bias would be inevitable. We decided not to do this in the present article, to produce tables of reasonable size. (iii) Many agents have also been tested in the Min mouse model, or similar models (e.g., truncated Apc, Msh2, Mlh1). The potency of dietary agents to decrease the number of polyps in these mice could be gathered and ranked in a table. Indeed, NSAIDs decrease the number of polyps in the small intestine of mutant mice. But surprisingly, some potent chemopreventive agents against chemically-induced tumors, namely PEG, celecoxib, piroxicam, sulindac, and DFMO can increase the polyp number or size in the colon of mutant mice (36, 300-304). The reason for this puzzling discrepancy is not clearly understood. It may be a result of differences in key enzymes in the small and large intestines (305). (iv) Any decision to test an agent in a human clinical trial should rely not only on the efficacy of the agent, but also on other considerations: lack of toxicity, the paucity of sideeffects, acceptability (e.g., no taste), and price. The chemopreventive doses reported in this review are not toxic for rats. It would be useful however to review accurately the human safety of these agents, but this is out of this paper scope.
A significant correlation was found between the potencies in the ACF assay and in the tumor assay ( fig. 2 ). This finding is weakened by a selection bias and a publication bias. This review gathers agents that inhibit ACF or tumors. It does not report null studies, or agents with promoting properties. Thus, the study could not show strong discrepancies between ACF and tumor data. For instance, an agent that reduces the number of ACF, but increases the tumor incidence could not appear in a correlation, e.g., 2-(carboxyphenyl) retinamide (73, 86). Moreover, many negative studies are never published, and this leads to a publication bias that we cannot overcome. However, out of 40 agents, Steele et al. showed that of the 30 agents tested as active in the ACF assay, 21 prevented colon cancer in rats (306). It is thus likely that correlation could remain true, even if discrepant agents were included in the study. Celecoxib is very potent against tumors, but not against ACF. It thus appeared as a major outlier in the tumor-ACF correlation ( fig. 2) . Three explanations may be given. Celecoxib could inhibit tumors at a late phase of carcinogenesis (182), maybe by reducing angiogenesis in tumors. It would not inhibit the growth of ACF, since they do not require extra-supply of blood. A second explanation is that celecoxib could inhibit the growth of intraepithelial neoplasia near lymphoid aggregates. These lesions may have a high potential to grow to cancers, but do not proturb in the gut lumen, and could not be counted as ACF (307). Last, the celecoxib potency on ACF may have been under-estimated by chance, or the potency on tumor over-estimated, since each value comes from a single study.
The present study does not prove that ACF are true preneoplastic lesions: maybe they never become cancers. Indeed, most of them do not, since the azoxymethane dose that yields one cancer per rat yields 100 to 200 ACF per colon. In contrast, the so-called "ACF min" (308), or the betacatenin accumulated crypts and ACF (21, 309), may be truly premalignant lesions for colon cancer. However, this study further supports the use of ACF as surrogate endpoint for tumors in rats. Because ACF can be detected easily without tissue sectioning, and because they correlate with the tumor outcome, they could remain a useful biomarker for the screening of agents for chemoprevention.
Finally, we propose that the potency of each new agent, or the result of each new chemoprevention study reported in the literature, should be compared with previously published agents. The present review shows that the median potency of effective agents published so far is two. A new agent that leads to a twofold reduction in the ACF number or in the tumor incidence is thus an average one. In contrast, an agent that reduces the ACF number or the tumor incidence more than fivefold is of outstanding potency. 25 b: Potency of each agent was estimated by ratio of value in control rats to value in treated rats. We used tumor data confirmed by histology, when available. For instance, in the study of Corpet et al. (28), incidence of tumors (confirmed by histology) was 22 of 27 in control group and 2 of 21 in rats given PEG: potency of PEG to reduce tumor incidence was calculated as (22/27)/(2/21) = 8.55. Potency is inverse of relative risk (e.g., a potency of 8.55 corresponds to a relative risk of 0.12).
c: Percent inhibition afforded by the agent is equal to (100 100/potency).
d: Values represent number of tumor-bearing rats per total number of rats or %tumor incidence in control and treated groups. Potency based on small numbers (<8) of tumor-bearing rats is not accurate (data in boldface). When no tumor was seen in control group, potency calculation was arbitrarily based on 0.5 tumors in the group. NR, not reported. 
